关于参加 2025 年广东辖区 广东众生药业股份有限公司董事会 投资者网上集体接待日活动的公告 二〇二五年九月十六日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。 届时公司董事长、总裁陈永红先生，董事、副总裁、财务总监龙春华女士， 董事会秘书杨威先生将在线就公司 2025 年半年度业绩、公司治理、发展战略、 经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 证券代码：002317 公告编号：2025-094 特此公告。 广东众生药业股份有限公司 为进一步加强与投资者的互动交流，广东众生药业股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价 值领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明 会"，现将相关事项公告如下： 第 1页 共 1页 ...

Group 1 - The core issue raised by investors regarding the supply of Anglatide tablets, which sold 50 units and then went out of stock [2] - Zhongsheng Pharmaceutical (002317.SZ) confirmed on the investor interaction platform that it is advancing the commercialization of Anglatide tablets and that there is sufficient supply both online and offline [2]

Core Viewpoint - The company is advancing the commercialization of Anglatide tablets, ensuring sufficient supply both online and offline [1] Group 1 - The company is actively working on the production and sales of the drug [1]

Group 1: Macro Economic Overview - In August, economic data continued to decline, following the weakening trend observed in July, with most indicators showing a downward trajectory [3] - Looking ahead, exports are expected to decline in the fourth quarter, with insufficient domestic demand in consumption, real estate, and prices remaining a constraint, leading to a short-term policy response that is likely to be supportive but not aggressive [3] - Specific areas of concern include a continued decline in consumption due to diminishing effects of trade-in policies, a rapid decline in investment across real estate, manufacturing, and infrastructure, and a slight decrease in industrial production [3] Group 2: Fixed Income Market Insights - Economic data indicates a comprehensive decline, suggesting increased downward pressure on the economy, with demand slowdown beginning to affect supply [5] - The fixed income market is expected to experience volatility in the short term, with a gradual recovery anticipated as various disruptive factors stabilize [6] - The high-frequency index for basic economic indicators stands at 127.6 points, with a year-on-year increase of 5.6 points, indicating stable yet cautious economic conditions [7] Group 3: AI and Storage Industry - The enterprise storage market is projected to reach approximately $87.8 billion by 2025, with a compound annual growth rate (CAGR) of about 18.7% from 2024 to 2028, driven by increasing AI demand [8] - AI server memory costs are significantly higher than traditional CPU servers, with DRAM costs for AI servers reaching $7,860 compared to $3,930 for CPU servers, highlighting the growing value of storage in AI applications [8] - Major storage manufacturers are raising prices due to supply constraints, with companies like SanDisk increasing flash memory prices by 10%, indicating a bullish trend in the storage market [10] Group 4: Company-Specific Insights - Dongyangguang (600673.SH) is strategically transforming to respond to the surging global demand for AI computing power, aiming to create a comprehensive ecosystem that integrates green energy, hardware technology, computing facilities, AI applications, and operational services [13] - The company is expected to achieve revenues of 15.7 billion, 24.8 billion, and 30 billion yuan from 2025 to 2027, with corresponding net profits of 1.4 billion, 2.2 billion, and 2.8 billion yuan, reflecting a strong growth trajectory [13] - Zhongsheng Pharmaceutical (002317.SZ) is experiencing steady growth, leveraging its advantages in new drug development technologies in the respiratory and metabolic disease sectors, with several products expected to yield positive results [18]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Group 1 - The core viewpoint emphasizes the importance of technology transfer in driving high-quality development in the healthcare industry, highlighting the collaboration between research institutions and pharmaceutical companies as a key factor in medical innovation [1][2][3] - The "Hundred Enterprises and Hundred Hospitals Guangdong Medical Tour" event aims to facilitate the integration of medical and engineering sectors, ensuring precise alignment between clinical needs and research efforts, thereby accelerating the commercialization of scientific achievements [2][8] - The first batch of 133 biomedicine technology transfer achievements was released, showcasing the need for improved conversion rates in the biomedicine sector, which currently faces challenges such as insufficient innovation and immature supply chains [3][4] Group 2 - Guangdong province leads the nation in the number of pharmaceutical and medical device production enterprises, with a total of 8,983 companies and over 1.76 million registered products as of June 2023 [4] - The biomedicine industry in Dongguan has matured over the past decade, with over 500 biopharmaceutical companies established, including notable leaders in various sub-sectors [9][10] - Dongguan's "Songhu Pharmaceutical Port" is positioned as a central hub for biopharmaceutical innovation, aiming to create a comprehensive ecosystem for research, incubation, and industrialization [10][11]

Core Insights - The emergence of Angladevi highlights the effective collaboration between clinical needs and basic research, showcasing a successful model of medical innovation through deep integration of medicine and modern engineering technology [1][3] - Guangdong province is leveraging the "Hundred Enterprises and Hundred Hospitals" initiative to enhance the integration of medical and industrial sectors, aiming to accelerate the transformation of scientific research achievements into practical applications [2][6] Industry Developments - The first batch of 133 key biopharmaceutical technology transformation achievements was released, including projects from various medical institutions and universities, aimed at fostering collaboration between academia and industry [3][6] - Guangdong's biopharmaceutical industry is experiencing significant growth, with the province leading the nation in the number of pharmaceutical and medical device production enterprises, as well as in the approval of innovative products [4][3] Challenges and Opportunities - The biopharmaceutical sector faces challenges such as low transformation rates of scientific achievements and the need for a more mature supply chain and manufacturing system [3][4] - The establishment of the Songhu Pharmaceutical Port as a specialized industrial park aims to create a comprehensive ecosystem for biopharmaceutical research and development, addressing the complexities and specialization of the industry [8][7] Future Directions - Guangdong plans to enhance its biopharmaceutical technology transformation system and incentives, further promoting the application of scientific achievements and the integration of production and sales [6][9] - The focus on building high-level medical institutions' support in drug and device development is expected to create more integrated medical and industrial scenarios, contributing to the establishment of Dongguan as a new hub for the biopharmaceutical industry [9][7]

证券日报网讯众生药业9月10日在互动平台回答投资者提问时表示，公司高度重视药品的国外市场机 会，将适时开展昂拉地韦片海外市场的拓展，探索更多可能性，加快国际化推进步伐。公司正推进该产 品的商业化工作，围绕学术生态构建、数据化服务升级及关键项目实践三大维度深化营销创新，持续拓 展多种销售渠道和提高市场占有率。 （文章来源：证券日报） ...

（编辑 王雪儿） 证券日报网讯 众生药业9月9日在互动平台回答投资者提问时表示，ZSP1601片是具有全新作用机制的治 疗代谢功能障碍相关脂肪性肝炎（MASH）的一类创新药，为国家重大新药创制项目，该项目正在开展 IIb期临床试验。公司高度重视药品的国外市场机会，积极寻求国际合作。如达到相关披露标准，公司 将严格根据信息披露规则及时履行信息披露义务。 ...

（编辑 王雪儿） 证券日报网讯 众生药业9月9日在互动平台回答投资者提问时表示，公司按照"中药为基、创新引领，聚 焦特色的医药健康企业"的战略目标定位，专注主业，努力提升业绩，并重视自身价值提升和股东价值 回报，切实保障中小投资者的权益。如有相关计划，公司将依据信息披露规则履行信息披露责任。 ...